Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norman L Block

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
The Prostate|September 23, 2010
Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelixBernadett Rozsa, Mehrdad Nadji, Andrew V Schally, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2010
Acceleration of wound healing by growth hormone-releasing hormone and its agonistsNikolina Dioufa, Andrew V Schally, Ioulia Chatzistamou, et al.
International Journal of Oncology|September 30, 2009
Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasiaBernadett Rózsa, Aliz Juhász, Andrea Treszl, et al.
Hormones & Cancer|March 24, 2012
Growth hormone-releasing hormone receptor splice variant 1 is frequently expressed in oral squamous cell carcinomasNikolina Dioufa, Elena Farmaki, Andrew V Schally, et al.
Cancer|July 14, 2011
Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancersAnna Klukovits, Andrew V Schally, Luca Szalontay, et al.
Oncotarget|June 8, 2013
Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108Karoly Szepeshazi, Andrew V Schally, Norman L Block, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancerCale D Fahrenholtz, Ferenc G Rick, Maria I Garcia, et al.
The Journal of Urology|February 21, 2012
Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkageFerenc G Rick, Luca Szalontay, Andrew V Schally, et al.
Cell Cycle (Georgetown, Tex.)|October 26, 2012
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancerFerenc G Rick, Stephan Seitz, Andrew V Schally, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaFerenc G Rick, Andrew V Schally, Norman L Block, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
The Prostate|September 23, 2010
Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelixBernadett Rozsa, Mehrdad Nadji, Andrew V Schally, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2010
Acceleration of wound healing by growth hormone-releasing hormone and its agonistsNikolina Dioufa, Andrew V Schally, Ioulia Chatzistamou, et al.
International Journal of Oncology|September 30, 2009
Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasiaBernadett Rózsa, Aliz Juhász, Andrea Treszl, et al.
Hormones & Cancer|March 24, 2012
Growth hormone-releasing hormone receptor splice variant 1 is frequently expressed in oral squamous cell carcinomasNikolina Dioufa, Elena Farmaki, Andrew V Schally, et al.
Cancer|July 14, 2011
Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancersAnna Klukovits, Andrew V Schally, Luca Szalontay, et al.
Oncotarget|June 8, 2013
Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108Karoly Szepeshazi, Andrew V Schally, Norman L Block, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancerCale D Fahrenholtz, Ferenc G Rick, Maria I Garcia, et al.
The Journal of Urology|February 21, 2012
Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkageFerenc G Rick, Luca Szalontay, Andrew V Schally, et al.
Cell Cycle (Georgetown, Tex.)|October 26, 2012
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancerFerenc G Rick, Stephan Seitz, Andrew V Schally, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaFerenc G Rick, Andrew V Schally, Norman L Block, et al.
Pageof 9